# Assessment of Efficacy of Mirabegron, a New beta3-adrenergic Receptor in the Prevention of Heart Failure

> **NCT02599480** · PHASE2 · COMPLETED · sponsor: **Jean-Luc Balligand** · enrollment: 296 (actual)

## Conditions studied

- Hypertrophy, Left Ventricular

## Interventions

- **DRUG:** mirabegron
- **PROCEDURE:** Echocardiography
- **PROCEDURE:** Cardiac MRI
- **PROCEDURE:** Maximal exercise capacity
- **PROCEDURE:** Blood sampling
- **PROCEDURE:** Endothelial function measurement
- **RADIATION:** 18FDG-PET

## Key facts

- **NCT ID:** NCT02599480
- **Lead sponsor:** Jean-Luc Balligand
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-12
- **Primary completion:** 2021-02-26
- **Final completion:** 2022-02-16
- **Target enrollment:** 296 (ACTUAL)
- **Last updated:** 2025-02-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02599480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02599480, "Assessment of Efficacy of Mirabegron, a New beta3-adrenergic Receptor in the Prevention of Heart Failure". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02599480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*